Active — Not RecruitingNot Applicable

Protein Ingestion on BMM Response in Endurance Runners

Canada14 participantsStarted 2024-03-01

Plain-language summary

The goal of this clinical trial is to investigate the effects of protein ingestion post-exercise on bone turnover markers. The main questions it aims to answer is: Does protein ingestion independently influence the bone metabolic response to exercise in endurance runners? We will compare dietary protein to a placebo (water) to detect changes in bone turnover markers. Participants will: In a within-subject design, participants will perform an exhaustive run and take either protein or placebo immediately post-exercise. Track physical activity and diet before each arm of the intervention and during the washout period.

Who can participate

Age range18 Years – 35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18-35 years of age * Healthy-range body mass index (BMI) (18.5-24.9 kg/m2) * Competitive runner for at least one season (minimum 40 km/week for the past 6-months) * Can read, speak, and understand French and/or English Exclusion Criteria: * Disease or medication known to affect bone metabolism * Disease (e.g., uncontrolled thyroid disease, malabsorptive or inflammatory disorder, metabolic bone disease) * Medication (e.g., hormonal contraceptives the past 3 months, glucocorticoids, anti-hypertensive drugs, anti-epileptic drugs, osteoporosis therapy) * Orthopedic or musculoskeletal injury/disease that limits the capacity to exercise * Current smoker or tobacco user * Current diagnosis of an eating disorder * Female participants with self-reported or diagnosed: * Hypothalamic amenorrhea * Polycystic ovarian syndrome * Hyperprolactinemia * Primary ovarian insufficiency * Pregnant or breastfeeding * Donated blood within the past two months

What they're measuring

Beta-C-terminal telopeptide

Timeframe: Up to 24 hours

Procollagen 1 Intact N-Terminal Propeptide

Timeframe: Up to 24 hours

Trial details

NCT IDNCT06645119

SponsorMcGill University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-24